Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer

OBJECTIVES: We aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-line treatment in KRAS wild-type (WT), pan-RAS WT a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shing Fung, Choi, Horace C. W., Chan, Sik Kwan, Lam, Ka On, Lee, Victor H. F., Wong, Irene O. L., Chiang, Chi Leung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127841/
https://www.ncbi.nlm.nih.gov/pubmed/34012917
http://dx.doi.org/10.3389/fonc.2021.651299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127841/
https://www.ncbi.nlm.nih.gov/pubmed/34012917
http://dx.doi.org/10.3389/fonc.2021.651299

Ejemplares similares